Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the α-adrenoceptor antagonist furobenzazepine

D. Fan, George Poste, R. R. Ruffolo, Z. Dong, C. Seid, L. E. Earnest, T. E. Campbell, R. K. Clyne, P. J. Beltran, I. J. Fidler

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The purpose of this study was to determine whether agonists and antagonists of α-adrenoceptors that affect calcium fluxes and protein kinase C signal transduction after the chemosensitivity of cancer cells that exhibit multidrug resistance (MDR). The effects of nine α-adrenoceptor agonists or antagonists on the in vitro chemosensitivity of the UV-2237 murine fibrosarcoma and its doxorubicin-selected MDR variants (UV-2237-R1 and UV-2237-R10) were examined. Noncytotoxic concentrations of the α-adrenoceptor antagonist furobenzazepine enhanced the antitumor activity of doxorubicin, actinomycin D, vinblastine and vincristine, but not 5-fluorouracil. Similar effects of furobenzazepine were also observed in recently established doxorubicin-resistant MDR variants of the CT-26 murine colon carcinoma. The chemosensitizing effect of furobenzazepine was associated with an increase in intracellular accumulation of anticancer drugs. Furobenzazepine did not compete with [3H]azidopine for photoaffinity labeling of P-glycoprotein, but it did produce a transient 30% reduction of P-glycoprotein in the MDR cells. These data indicate that furobenzazepine can reverse a P-glycoprotein-mediated experimental MDR phenotype.

Original languageEnglish (US)
Pages (from-to)789-798
Number of pages10
JournalInternational Journal of Oncology
Volume4
Issue number4
StatePublished - 1994
Externally publishedYes

Fingerprint

Fibrosarcoma
Multiple Drug Resistance
Adrenergic Receptors
Colon
Carcinoma
P-Glycoprotein
Doxorubicin
Vinblastine
Dactinomycin
Vincristine
Fluorouracil
Protein Kinase C
Signal Transduction
Calcium
Phenotype
Pharmaceutical Preparations
Neoplasms

Keywords

  • MDR-reversal
  • P-glycoprotein

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the α-adrenoceptor antagonist furobenzazepine. / Fan, D.; Poste, George; Ruffolo, R. R.; Dong, Z.; Seid, C.; Earnest, L. E.; Campbell, T. E.; Clyne, R. K.; Beltran, P. J.; Fidler, I. J.

In: International Journal of Oncology, Vol. 4, No. 4, 1994, p. 789-798.

Research output: Contribution to journalArticle

Fan, D, Poste, G, Ruffolo, RR, Dong, Z, Seid, C, Earnest, LE, Campbell, TE, Clyne, RK, Beltran, PJ & Fidler, IJ 1994, 'Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the α-adrenoceptor antagonist furobenzazepine', International Journal of Oncology, vol. 4, no. 4, pp. 789-798.
Fan, D. ; Poste, George ; Ruffolo, R. R. ; Dong, Z. ; Seid, C. ; Earnest, L. E. ; Campbell, T. E. ; Clyne, R. K. ; Beltran, P. J. ; Fidler, I. J. / Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the α-adrenoceptor antagonist furobenzazepine. In: International Journal of Oncology. 1994 ; Vol. 4, No. 4. pp. 789-798.
@article{83cf36bfbd0547f6a19b01ff5f0d128d,
title = "Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the α-adrenoceptor antagonist furobenzazepine",
abstract = "The purpose of this study was to determine whether agonists and antagonists of α-adrenoceptors that affect calcium fluxes and protein kinase C signal transduction after the chemosensitivity of cancer cells that exhibit multidrug resistance (MDR). The effects of nine α-adrenoceptor agonists or antagonists on the in vitro chemosensitivity of the UV-2237 murine fibrosarcoma and its doxorubicin-selected MDR variants (UV-2237-R1 and UV-2237-R10) were examined. Noncytotoxic concentrations of the α-adrenoceptor antagonist furobenzazepine enhanced the antitumor activity of doxorubicin, actinomycin D, vinblastine and vincristine, but not 5-fluorouracil. Similar effects of furobenzazepine were also observed in recently established doxorubicin-resistant MDR variants of the CT-26 murine colon carcinoma. The chemosensitizing effect of furobenzazepine was associated with an increase in intracellular accumulation of anticancer drugs. Furobenzazepine did not compete with [3H]azidopine for photoaffinity labeling of P-glycoprotein, but it did produce a transient 30{\%} reduction of P-glycoprotein in the MDR cells. These data indicate that furobenzazepine can reverse a P-glycoprotein-mediated experimental MDR phenotype.",
keywords = "MDR-reversal, P-glycoprotein",
author = "D. Fan and George Poste and Ruffolo, {R. R.} and Z. Dong and C. Seid and Earnest, {L. E.} and Campbell, {T. E.} and Clyne, {R. K.} and Beltran, {P. J.} and Fidler, {I. J.}",
year = "1994",
language = "English (US)",
volume = "4",
pages = "789--798",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the α-adrenoceptor antagonist furobenzazepine

AU - Fan, D.

AU - Poste, George

AU - Ruffolo, R. R.

AU - Dong, Z.

AU - Seid, C.

AU - Earnest, L. E.

AU - Campbell, T. E.

AU - Clyne, R. K.

AU - Beltran, P. J.

AU - Fidler, I. J.

PY - 1994

Y1 - 1994

N2 - The purpose of this study was to determine whether agonists and antagonists of α-adrenoceptors that affect calcium fluxes and protein kinase C signal transduction after the chemosensitivity of cancer cells that exhibit multidrug resistance (MDR). The effects of nine α-adrenoceptor agonists or antagonists on the in vitro chemosensitivity of the UV-2237 murine fibrosarcoma and its doxorubicin-selected MDR variants (UV-2237-R1 and UV-2237-R10) were examined. Noncytotoxic concentrations of the α-adrenoceptor antagonist furobenzazepine enhanced the antitumor activity of doxorubicin, actinomycin D, vinblastine and vincristine, but not 5-fluorouracil. Similar effects of furobenzazepine were also observed in recently established doxorubicin-resistant MDR variants of the CT-26 murine colon carcinoma. The chemosensitizing effect of furobenzazepine was associated with an increase in intracellular accumulation of anticancer drugs. Furobenzazepine did not compete with [3H]azidopine for photoaffinity labeling of P-glycoprotein, but it did produce a transient 30% reduction of P-glycoprotein in the MDR cells. These data indicate that furobenzazepine can reverse a P-glycoprotein-mediated experimental MDR phenotype.

AB - The purpose of this study was to determine whether agonists and antagonists of α-adrenoceptors that affect calcium fluxes and protein kinase C signal transduction after the chemosensitivity of cancer cells that exhibit multidrug resistance (MDR). The effects of nine α-adrenoceptor agonists or antagonists on the in vitro chemosensitivity of the UV-2237 murine fibrosarcoma and its doxorubicin-selected MDR variants (UV-2237-R1 and UV-2237-R10) were examined. Noncytotoxic concentrations of the α-adrenoceptor antagonist furobenzazepine enhanced the antitumor activity of doxorubicin, actinomycin D, vinblastine and vincristine, but not 5-fluorouracil. Similar effects of furobenzazepine were also observed in recently established doxorubicin-resistant MDR variants of the CT-26 murine colon carcinoma. The chemosensitizing effect of furobenzazepine was associated with an increase in intracellular accumulation of anticancer drugs. Furobenzazepine did not compete with [3H]azidopine for photoaffinity labeling of P-glycoprotein, but it did produce a transient 30% reduction of P-glycoprotein in the MDR cells. These data indicate that furobenzazepine can reverse a P-glycoprotein-mediated experimental MDR phenotype.

KW - MDR-reversal

KW - P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=0028266151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028266151&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028266151

VL - 4

SP - 789

EP - 798

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -